CLAIM CARD
Mechanistically, the rationale linking PCSK9 inhibition to cardiometabolic longevity rests on lipid-lowering and vascular aging pathways. Liu 2023 provided preclinical data showing that PCSK9 attenuates efferocytosis in endothelial cells, thereby promoting vascular aging, with experiments conducted in PCSK9 knockout mice and aging wild-type mice administered a PCSK9 inhibitor (Pep2-8, 10 µg/kg body weight over 2 weeks). Together, clinical RCT evidence from Wang 2022 and mechanistic human and preclinical studies from Liu 2023 suggest biological plausibility for PCSK9 inhibition attenuating vascular aging, though direct longevity endpoints remain sparse.
Evidence grade: exploratory
Contradiction status: none
Publication: 4753c82f-24d3-490c-8a23-6cc8d4194c24
Provenance: Derivation Web chain
Citation Support
source_1Ma 2025source_2Schwartz 2021source_3Lehrke 2024source_4Imran 2023source_5Faraidy 2023